2016-12892. Government-Owned Inventions; Availability for Licensing  

  • Start Preamble

    AGENCY:

    National Institutes of Health.

    ACTION:

    Notice.

    SUMMARY:

    The inventions listed below are owned by an agency of the U.S. Government and are available for licensing in the U.S. in accordance with 35 U.S.C. 209 and 37 CFR part 404 to achieve expeditious commercialization of results of federally-funded research and development.

    Start Further Info

    FOR FURTHER INFORMATION CONTACT:

    Licensing information may be obtained by emailing the indicated licensing contact at the National Heart, Lung, and Blood, Office of Technology Transfer and Development Office of Technology Transfer, 31 Center Drive Room 4A29, MSC2479, Bethesda, MD 20892-2479; telephone: 301-402-5579. A signed Confidential Disclosure Agreement may be required to receive any unpublished information.

    End Further Info End Preamble Start Supplemental Information

    SUPPLEMENTARY INFORMATION:

    Technology description follows.

    Albumin Binding Immunomodulatory Compositions

    The invention relates to molecules wherein Evan's Blue dye is chemically conjugated to CpG Oligonucleotides that elicit anti-tumoral or infection fighting immunity. Evans Blue, a symmetric azo dye, has high binding affinity to albumin. Albumin binding ability of Evans blue is utilized with CpGs and tumor-specific antigens, in order to leverage endogenous albumin that increases the safety and the potency of molecular vaccines. As such, the molecular entities provided here enable efficient delivery and prolonged retention in lymph nodes and reduce systemic toxicity of Evans Blue and enhanced the therapeutic potency of molecular vaccines.

    Potential Commercial Applications:

    • Cancer therapeutics
    • Infectious disease therapeutics
    • Lymph node specificity
    • Higher stability/Lower toxicity

    Development Stage:

    • Early stage
    Start Printed Page 35373

    Inventors: Xiaoyuan Chen and Guizhi Zhu (both of NIBIB).

    Intellectual Property: HHS Reference No. E-149-2016/0; U.S. Provisional Patent Applications 62/331,890 filed May 4, 2016.

    Licensing Contact: Michael Shmilovich, Esq, CLP; 301-435-5019; shmilovm@mail.nih.gov.

    Start Signature

    Dated: May 26, 2016.

    Michael Shmilovich,

    Senior Licensing and Patenting Manager, National Heart, Lung, and Blood Institute, Office of Technology Transfer and Development.

    End Signature End Supplemental Information

    [FR Doc. 2016-12892 Filed 6-1-16; 8:45 am]

    BILLING CODE 4140-01-P

Document Information

Published:
06/02/2016
Department:
National Institutes of Health
Entry Type:
Notice
Action:
Notice.
Document Number:
2016-12892
Pages:
35372-35373 (2 pages)
PDF File:
2016-12892.pdf